AKEBIA THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
AKEBIA THERAPEUTICS, INC. (AKBA) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $7.28 million for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-11-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2015-11-09
- AKEBIA THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2015-09-30 was $8.26M, a 297.26% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2015-06-30 was -$2.88M.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2015-03-31 was $1.90M, a 0.68% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2014-12-31 was $378.00K, a 164.34% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2014 was $4.06M, a 78.74% increase from fiscal 2013.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2013 was $2.27M.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2012 was -$1.05M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 85 month |
|---|---|---|---|---|---|---|---|
| 2015-09-30 | $8.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $5.38M derived: sum of 2 quarters · filed 2015-11-09 | $7.28M 10-Q · filed 2015-11-09 | $7.65M derived: sum of 4 quarters · filed 2015-11-09 | |||
| 2015-06-30 | -$2.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | -$987.00K 10-Q · filed 2015-08-11 | -$609.00K derived: sum of 3 quarters · filed 2015-08-11 | $1.47M derived: sum of 4 quarters · filed 2015-11-09 | |||
| 2015-03-31 | $1.90M 10-Q · filed 2015-05-11 | $2.27M derived: sum of 2 quarters · filed 2015-05-11 | $4.36M derived: sum of 3 quarters · filed 2015-11-09 | $4.05M derived: sum of 4 quarters · filed 2015-11-09 | |||
| 2014-12-31 | $378.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-04 | $2.46M derived: sum of 2 quarters · filed 2015-11-09 | $2.15M derived: sum of 3 quarters · filed 2015-11-09 | $4.06M 10-K · filed 2015-03-04 | |||
| 2014-09-30 | $2.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $1.77M derived: sum of 2 quarters · filed 2015-11-09 | $3.68M 10-Q · filed 2015-11-09 | $3.83M derived: sum of 4 quarters · filed 2015-11-09 | |||
| 2014-06-30 | -$307.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | $1.60M 10-Q · filed 2015-08-11 | $1.60M 10-Q · filed 2014-08-11 | $1.75M derived: sum of 3 quarters · filed 2015-08-11 | $2.58M derived: sum of 4 quarters · filed 2015-08-11 | ||
| 2014-03-31 | $1.91M 10-Q · filed 2015-05-11 | $1.91M 10-Q · filed 2014-05-12 | $2.05M derived: sum of 2 quarters · filed 2015-05-11 | $2.89M derived: sum of 3 quarters · filed 2015-05-11 | $3.73M derived: sum of 4 quarters · filed 2015-05-11 | $5.53M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $143.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-04 | $978.27K derived: sum of 2 quarters · filed 2015-03-04 | $1.82M derived: sum of 3 quarters · filed 2015-03-04 | $2.27M 10-K · filed 2015-03-04 | |||
| 2013-09-30 | $835.27K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $1.68M derived: sum of 2 quarters · filed 2014-11-10 | $2.13M 10-Q · filed 2014-11-10 | ||||
| 2013-06-30 | $841.28K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $1.29M 10-Q · filed 2014-08-11 | |||||
| 2013-03-31 | $452.44K 10-Q · filed 2014-05-12 | ||||||
| 2012-12-31 | -$1.05M 10-K · filed 2015-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |